GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Clonidine - ONYDA XR oral suspension

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug3 sources available - open source summaries, references and comparisons

ONYDA XR / Clonidine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

No dialysis supplement does not mean an unadjusted starting dose

The selected official and mirror paragraphs require impairment-based initiation and cautious titration, but give no numerical renal ladder.

Before applying: Keep the no-supplement statement separate from starting-dose assessment and other clonidine products.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
ONYDA XR: no post-HD supplement does not establish the starting dose

Minimal removal during routine HD does not cancel the need for impairment-based initiation and cautious titration.

Before applying: Monitor hypotension and bradycardia; do not invent a pediatric renal table.

Also check: ONYDA XR: no post-HD supplement does not establish the starting dose

Official source

Clonidine - ONYDA XR extended-release oral suspension

Product / population
ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.
Renal measure
Qualitative impairment; no validated numeric renal algorithm
Before using this finding

Do not convert the standard starting dose into a renal starting-dose recommendation.

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Renal dosing, restrictions and evidence limits

Section 8.6 directs an initial dose based on renal impairment, careful monitoring for hypotension/bradycardia and cautious upward titration; pediatric renal pharmacokinetics remain unassessed. No numeric renal ladder is supplied. Because routine hemodialysis removes only a minimal amount, supplemental ONYDA XR after dialysis is unnecessary.

Measure heart rate and blood pressure before starting, after dose increases and periodically. The product is not interchangeable mg-for-mg with other clonidine formulations. Avoid abrupt withdrawal: the label requires gradual tapering to reduce rebound-hypertension risk. This is not a recommendation to use an unadjusted starting dose in renal impairment.

Source revision: 4/2025 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a15c850-9da5-4bdc-a34d-7f740a6149b7

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Clonidine - ONYDA XR extended-release oral suspension

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

GlobalRPh RX List - ONYDA XR

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Clonidine - ONYDA XR extended-release oral suspension

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Do not convert the standard starting dose into a renal starting-dose recommendation.

Dialysis evidence: A regimen is reported in selected content

ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.

Renal method: Qualitative impairment; no validated numeric renal algorithm
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ONYDA XR

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Clonidine - ONYDA XR oral suspension; selected source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal statement; no numerical renal algorithm inferred.
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ONYDA XR

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Cautious titration is required despite no post-HD supplement.

Dialysis evidence: A regimen is reported in selected content

ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.

Renal method: Qualitative degree of renal impairment; no numerical bands
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

ONYDA XR: no post-HD supplement does not establish the starting doseNo dialysis supplement does not mean an unadjusted starting dose

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dialysis scope

ONYDA XR: no post-HD supplement does not establish the starting dose

Minimal removal during routine HD does not cancel the need for impairment-based initiation and cautious titration.

How to use this: Monitor hypotension and bradycardia; do not invent a pediatric renal table.

GlobalRPh RX List - ONYDA XRClonidine extended-release tablets (KAPVAY)

Source-specific interpretation; independent clinician adjudication pending.

titration versus dialysis supplement

No dialysis supplement does not mean an unadjusted starting dose

The selected official and mirror paragraphs require impairment-based initiation and cautious titration, but give no numerical renal ladder.

How to use this: Keep the no-supplement statement separate from starting-dose assessment and other clonidine products.

GlobalRPh RX List - ONYDA XRClonidine - ONYDA XR extended-release oral suspensionClonidine extended-release tablets (KAPVAY)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeClonidine - ONYDA XR extended-release oral suspensionGlobalRPh RX List - ONYDA XRGlobalRPh RX List - ONYDA XR
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/onyda-xr-drug/

Exact product and population

Clonidine - ONYDA XR oral suspension; selected source sections only, not a complete prescribing monograph.

RDM49-SCOPE-clonidine-onyda-xr · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Clonidine - ONYDA XR extended-release oral suspension

Open original reference

Open / share this exact local source

DailyMed / NextWave Pharmaceuticals, Inc · ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.

Renal method: Qualitative impairment; no validated numeric renal algorithm
Source date: 4/2025
Retrieved: 2026-09-10

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Do not convert the standard starting dose into a renal starting-dose recommendation.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Section 8.6 directs an initial dose based on renal impairment, careful monitoring for hypotension/bradycardia and cautious upward titration; pediatric renal pharmacokinetics remain unassessed. No numeric renal ladder is supplied. Because routine hemodialysis removes only a minimal amount, supplemental ONYDA XR after dialysis is unnecessary.

Measure heart rate and blood pressure before starting, after dose increases and periodically. The product is not interchangeable mg-for-mg with other clonidine formulations. Avoid abrupt withdrawal: the label requires gradual tapering to reduce rebound-hypertension risk. This is not a recommendation to use an unadjusted starting dose in renal impairment.

RDM59-official-clonidine-onyda-xr-90b6d5fc1b-C1 · Source locator: Sections 8.6, 5.1, 2.3 and 2.4

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a15c850-9da5-4bdc-a34d-7f740a6149b7
Retrieved
2026-09-10
Exact label title
Clonidine - ONYDA XR extended-release oral suspension
DailyMed Set ID
4a15c850-9da5-4bdc-a34d-7f740a6149b7
Labeler
NextWave Pharmaceuticals, Inc
DailyMed page updated
2025-04-11
Label revision
4/2025
Renal-function method
Qualitative impairment; no validated numeric renal algorithm
Source date/version
4/2025
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
97593b03cb108681e32b8ff94238efde6fd849a1deccbd215f840a41b5136437
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ONYDA XR

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Clonidine - ONYDA XR oral suspension; selected source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal statement; no numerical renal algorithm inferred.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Pediatric renal PK has not been assessed. Base the initial dosage on the degree of renal impairment, monitor hypotension and bradycardia, and titrate cautiously. The selected renal passage gives no numerical starting schedule. Routine hemodialysis removes little clonidine, so a post-dialysis ONYDA XR supplement is not needed. This does not establish that the usual initial dose is appropriate in every renally impaired patient.

RDM49-rxlist-clonidine-onyda-xr-c7fb3c5dc9-C1 · Source locator: Use in Specific Populations: renal impairment, lines 352-354; cardiovascular precautions.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/onyda-xr-drug/
Retrieved
2026-09-09
Renal-function method
Qualitative renal statement; no numerical renal algorithm inferred.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b96ff7ffce3b45b0fb475a7e19dd8a1b14b1eee4e15358039e6478176733f7d9
Rxlist

GlobalRPh RX List - ONYDA XR

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.

Renal method: Qualitative degree of renal impairment; no numerical bands
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Cautious titration is required despite no post-HD supplement.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Pediatric renal pharmacokinetics have not been assessed. Base the initial dose on the degree of impairment, monitor hypotension and bradycardia, and increase cautiously. The source does not supply numerical CrCl bands. Routine hemodialysis removes little clonidine, so a post-dialysis supplement is not required in the selected paragraph.

Differing exposure profiles mean the suspension must not be substituted milligram-for-milligram for other clonidine products.

RDM59-rxlist-clonidine-onyda-xr-c7fb3c5dc9-C1 · Source locator: Renal Impairment; formulation pharmacokinetics

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/onyda-xr-drug/
Retrieved
2026-09-10
Renal-function method
Qualitative degree of renal impairment; no numerical bands
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e2373f8ff36ad835c9ba8381df5ed24108251af81e92ee2601b22f0868b6f32a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/onyda-xr-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
fed025af309bbffcf3e1d2d3f144e4e8aa797b3b6c273766bd22fddd0d00b5fe
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report